Canada, Canadian Institutes of Health Research; paid educational presentations, honoraria for symposia at the American Academy of Neurology. M.C.: board member- ship, GENMAB; consultancy, Biogen, Genzyme; grants/ grants pending, Bayer Schering, Biogen Elan, Novartis, Merck Serono, Sanofi-Aventis, Teva. J.A.C.: travel ex- penses, US NMSS; consultancy, Biogen Idec, Lilly, Novartis, Serono, Teva; grants/grants pending, Depart- ment of Defense, NIH, US NMSS; speaking fees, Biogen Idec, Novartis, Sanofi-Aventis, Waterfront Media. M.F.: travel expenses, US NMSS, ECTRIMS, MSIF, MS Ireland; board membership, Teva Pharmaceutical Indus- tries Ltd, Genmab A/S; consultancy, Bayer Schering Pharma, Biogen-Dompe´ AG, Genmab A/S, Merck Serono, Pepgen Corporation, Teva Pharmaceutical Industries Ltd; grants/grants pending, Bayer-Schering, Biogen-Dompe´ AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd, Fondazione Italiana Sclerosi Multipla, Fondazione Mariani; speaking fees, Bayer Schering Pharma, Biogen-Dompe´ AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd; travel expenses, Teva, Biogen-Dompe´ AG, Merck-Serono, Sanofi-Aventis, Gen- mab, Bayer Schering. K.F.: travel expenses, US NMSS, ECTRIMS, MSIF, MS Ireland; consultancy, Bayer Scher- ing Pharma, Biogen Idec, Merck Serono; grants/grants pending, Bayer Schering Pharma, Biogen Idec, Asahi Kasei Kuraray Medical Co Ltd, Chemo-Sero-Therapeutic Re- search Institute, Mitsubishi Tanabe Pharma, Teijin Phar- ma, Theva Pharmaceutical, Eisai Inc, Kowa Pharmaceu- tical, Ministry of Education, Science, and Technology of Japan, Ministry of Health, Labor, and Welfare of Japan; speaking fees, Bayer Schering Pharma, Biogen Idec, Eisai Inc, Mitsubishi Tanabe Pharma, Astellas Pharma, Takeda Pharmaceutical Company Ltd, Asahi Kasei Kuraray Medical Co; paid manuscript preparation, Cosmic Cor- poration; royalties, Bunkodo. E.H.: travel expenses, US NMSS, ECTRIMS, MSIF, MS Ireland; consultancy, Biogen Idec, Genzyme, Merck Serono, Novartis, Grifols; grants/grants pending, Biogen Idec; speaking fees, Biogen Idec, Genzyme, Merck Serono, Novartis, Bayer Healthcare, Sanofi-Aventis; paid educational presentations, Novartis. M.H.: consultancy, Biogen Idec; grant/grants pending, Health Research Board Ireland; speaking fees, Biogen Idec. L.K.: travel expenses, US NMSS; board membership, Editorial Board of Multiple Sclerosis; grants/grants pend- ing, National Research Foundation Switzerland, Rubatto Foundation, Swiss MS society, European Union, Roche Foundation, Novartis Foundation; speaking fees, various companies involved in development of MS therapeutics; paid educational presentations, Neurostatus System for Standardized Neurological Assessment. F.D.L.: travel support, US NMSS; consultancy, Novartis, Bayer, Biogen February 2011 Polman et al: 2010 Revisions to MS Diagnosis Idec, EMD Serono, Genentech, Teva Neuroscience, Genmab, Medicinova, Actelion, Allozyne, Sanofi-Aventis, Acorda, Questcor, Avanir, Roche, Celgene, Abbott, Pfizer, Morphosys; grants/grants pending, NIH, NMSS, Acorda, Biogen Idec, Teva, Novartis, Sanofi-Aventis; speaking fees, Genzyme, Teva, EMD Serono; paid educational presenta- tions, various continuing medical education services; stock/ stock options, cognition pharmaceuticals. X.M.: travel expenses, US NMSS; consultancy, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Almirall; grants/grants pending, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novar- tis, Sanofi-Aventis, Teva Pharmaceuticals, Almirall; speak- ing fees, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi- Aventis, Teva Pharmaceuticals, Almirall. M.S.-W.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; fees for review activities, Genentech, Merck Serono, Roche; board membership, Board of Directors of Active Biotech, Sweden; consultancy, Elan, Merck Serono; speaking fees, Bayer Health Care, Merck Serono, Serono Symposia International Foundation, Sanofi-Aventis, Swedish Bank SEB. A.J.T.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; board membership, National Hospital Devel- opment Foundation, Patrick Berthoud Charitable Trust; consultancy, Weleda AG/Society for Clinical Research, Medical Research Council, MS Society of Great Britain, Merck Serono, Biogen Idec, DIGNA Biotech, Novartis, Eisai London Research Laboratories, Teva Pharmaceuticals; grants/grants pending, National Institute for Health Research, MS Society of Great Britain; speaking fees, Serono Symposia, Sanofi-Aventis; travel expenses, MS International Federation, US NMSS, Biogen Idec; honor- aria, Editor-in-Chief of Multiple Sclerosis. E.W.: con- sultancy, Roche, Actelion; grants/grants pending, US NMSS, NIH; speaking fees, Teva; received free drug for a trial given by Sanofi-Aventis and Biogen Idec. B.W.: travel support, US NMSS; European Committee for Treatment of MS; MS International Foundation; MS Ireland; consultancy, Novartis, Biogen Idec; employment, Mayo Clinic; royalties, RSR Ltd. J.S.W.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; board membership, Antisense Therapeutics Ltd, BCDecker, Novartis Pharmaceuticals, Sanofi-Aventis, Teva Pharma- ceuticals, Eli Lilly, UCB; consultancy, Genentech, Novartis Pharmaceuticals, Sanofi-Aventis, Teva Neuroscience, Teva Pharmaceuticals, Acorda, Acetilon, Bayer HealthCare, Facet Biotech, Peptimmune; grants/grants pending, NIH, Sanofi-Aventis, Clayton Foundation for Research, US NMSS; honoraria for lectures, Consortium MS Centers, Sanofi-Aventis New Zealand, Sterling Meeting Services, 299